Kadmon Holdings Inc was established in Delaware in September 2010. The Company is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics within autoimmune and fibrotic diseases, oncology and genetic diseases. Its product candidates include KD025, Tesevatinab in oncology, Tesevatinab in Polycystic Kidney disease and KD034. It also markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus (HCV) infection. It competes directly with companies that focus on psoriasis, IPF, cGVHD, NSCLC with brain metastases and/or leptomeningeal metastases and PKD, and companies dedicating their resources to novel forms of therapies for these indications.